Cost-effectiveness of chemotherapy in non-small-cell lung cancer - In reply

被引：0
|
作者：
Leighl, NB [1 ]
Shepherd, FA
Goodwin, PJ
机构：
[1] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Toronto, ON, Canada
[2] Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2002年 / 20卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3751 / 3752
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Li, Yan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [32] Cost-effectiveness of stereotactic body radiotherapy in the treatment of non-small-cell lung cancer (NSCLC): a systematic review
    Sun, Hui
    Jin, Chunlin
    Wang, Huishan
    Hu, Shanlian
    Chen, Yingyao
    Wang, Haiyin
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (05) : 723 - 734
  • [33] Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan
    Leung, John Hang
    Chih-Wen Chang
    Chan, Agnes L. F.
    Hui-Chu Lang
    FUTURE ONCOLOGY, 2022, 18 (07) : 859 - 870
  • [34] Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China
    Zhang, Xiaoyu
    Fan, Xiongxiong
    Zhang, Jin
    Jiang, Fengli
    Wu, Yiping
    Yang, Beibei
    Li, Xinghuan
    Liu, Dong
    FRONTIERS IN PUBLIC HEALTH, 2024, 12
  • [35] Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China
    Gong, Jinhong
    Su, Dan
    Shang, Jingjing
    Xu, Shan
    Tang, Lidan
    Sun, Zhiqiang
    Liu, Guangjun
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [36] The use, cost, and cost-effectiveness of chemotherapy for nonsmall cell lung cancer
    Ramsey, Scott David
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S211 - S211
  • [37] Cost-Effectiveness Analysis of Gefitinib Alone and Combined with Chemotherapy as First-Line Treatment for Patients with Advanced Non-Small-Cell Lung Cancer
    Wang, Yao
    Huang, Kaiyu
    Sun, Sijia
    Deng, Yahong
    Xie, Xuefeng
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2022, 15 : 351 - 359
  • [38] Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
    Shu, Yamin
    Zhang, Qilin
    He, Xucheng
    Chen, Li
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8297 - 8306
  • [39] Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US
    Insinga, Ralph P.
    Vanness, David J.
    Feliciano, Josephine L.
    Vandormael, Kristel
    Traore, Sory
    Ejzykowicz, Flavia
    Burke, Thomas
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (07) : 1241 - 1256
  • [40] First-line treatment with durvalumab plus chemotherapy versus chemotherapy alone for metastatic non-small-cell lung cancer in the USA: a cost-effectiveness analysis
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    BMJ OPEN, 2023, 13 (12):
12345